Your SlideShare is downloading. ×
EUPATI Launch Meeing: Anders Olauson
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

EUPATI Launch Meeing: Anders Olauson


Published on

EUPATI Launch Meeting, 27 March 2012, Copenhagen: Anders Olauson

EUPATI Launch Meeting, 27 March 2012, Copenhagen: Anders Olauson

Published in: Health & Medicine, Business
1 Like
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. A paradigm shift in public understanding of medical R&DAnders Olauson, President European Patients’ Forum
  • 2. Unmet needs for most patientswith life-threatening diseases “Success stories” available only to small numbers of rare cancers, rare diseases, other life-threatening conditions, young and very old patients Patients need therapeutic innovation – urgently!Source: RareCare (2012)
  • 3. Patients need innovation --paradigm shift in drug developmentInnovation turns e.g. cancer,rare diseases upside down: Molecular targets/pathways New approaches Genome sequencing, needed Translational research  clinical trial design Personalized medicine  trial recruitment • Small trial populations  relationship • Biomarkers required between Need for post-marketing data researchers, Health Technology Assessment, regulators, industry, QoL, endpoints, comparators patients Healthcare budgets vs drug pricing
  • 4. Overcoming public scrutinyon research Lack of public confidence in research leads to • lack of trial recruitment (6-12% of cancer patients take part in research) • delayed generation of meaningful clinical data • slow progress or lack of research • bad image of research in population Objective information to the public & more transparency urgently needed
  • 5. Patients orgs: key role in buildingnew environment for drugdevelopment Patient organisations have unique insights in „real life“ and „real needs“ of patients: • Gap analysis in research priorities • Clinical trial design • Priority setting in healthcare budgets Driving force • Research policy Co-researcher Reviewer Training required to get expertise Advisor required to contribute to scientific projects Info provider Research subject Source: PatientPartner FP7 Project (2010)
  • 6. EUPATI: The paradigm shift ininvolving patients in medical R&D Great individual initiatives to train patient advocates - by patient organisations, academia, industry, healthcare professionals, Complemented by: The Patients’ Academy – a paradigm shift in collaborative efforts of all stakeholders to make drug development more effective in Europe Wishing you success!
  • 7. Get to know us! Web: Twitter: @eupatients as well as: